Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su) and EMAP II. Cell proliferation and protein expression were analyzed by WST-1 assay and Western blotting. In vivo experiments were performed via murine xenografts. Inhibition of in vitro proliferation of AsPC-1 PDAC cells by gemcitabine (10 μM), bevacizumab (1 mg/ml), sunitinib (10 μM) and EMAP (10 μM) was 35, 22, 81 and 6 percent; combination of gemcitabine with bevacizumab, sunitinib or EMAP had no additive effects. In endothelial HUVECs, gemcitabine, bevacizumab, sunitinib and EMAP caused 70, 41, 86 and 67 percent inhibition, while combination of gemcitabine with bevacizumab, sunitinib or EMAP had additive effects. In WI-38 fibroblasts, gemcitabine, bevacizumab, sunitinib and EMAP caused 79, 58, 80 and 29 percent inhibition, with additive effects in combination as well. Net in vivo tumor growth inhibition in gemcitabine, bevacizumab, sunitinib and EMAP monotherapy was 43, 38, 94 and 46 percent; dual combinations of Gem+Bev, Gem+Su and Gem+EMAP led to 69, 99 and 64 percent inhibition. Combinations of more than one antiangiogenic agent with gemcitabine were generally more effective but not superior to Gem+Su. Intratumoral proliferation, apoptosis and microvessel density findings correlated with tumor growth inhibition data. Median animal survival was increased by gemcitabine (26 days) but not by bevacizumab, sunitinib or EMAP monotherapy compared to controls (19 days). Gemcitabine combinations with bevacizumab, sunitinib or EMAP improved survival to similar extent (36 or 37 days). Combinations of gemcitabine with Bev+EMAP (43 days) or with Bev+Su+EMAP (46 days) led to the maximum survival benefit observed. Combination of antiangiogenic agents improves gemcitabine response, with sunitinib inducing the strongest effect. These findings demonstrate advantages of combining multi-targeting agents with standard gemcitabine therapy for PDAC.
References
[1]
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
[2]
Brennan MF (2004) Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 13: 555–566, vii.
[3]
Rosewicz S, Wiedenmann B (1997) Pancreatic carcinoma. Lancet 349: 485–489.
[4]
Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V (2006) Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 7: 34–40.
[5]
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, et al. (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6: 369–376.
[6]
Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, et al. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776–3783.
[7]
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509–3516.
[8]
Garcea G, Lloyd TD, Gescher A, Dennison AR, Steward WP, et al. (2004) Angiogenesis of gastrointestinal tumours and their metastases–a target for intervention? Eur J Cancer 40: 1302–1313.
[9]
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, et al. (2008) A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 26: 463–471.
[10]
Dragovich T, Burris H, Loehrer P, Von Hoff DD, Chow S, et al. (2008) Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 31: 157–162.
[11]
Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, et al. (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161–167.
[12]
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966.
[13]
Korc M (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2: 8.
[14]
Luo J, Guo P, Matsuda K, Truong N, Lee A, et al. (2001) Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 92: 361–369.
[15]
Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85: 27–34.
[16]
Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H (2002) Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 9: 633–640.
[17]
Cabebe E, Fisher GA (2007) Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. Expert Opin Investig Drugs 16: 467–476.
[18]
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–478.
[19]
O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, et al. (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597–3605.
[20]
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327–337.
[21]
Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, et al. (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011–1021.
[22]
Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, et al. (1998) Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 34: 1439–1447.
[23]
Korc M (2007) Pancreatic cancer-associated stroma production. Am J Surg 194: S84–86.
[24]
Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, et al. (2008) Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37: 145–150.
[25]
Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, et al. (2008) SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71: 873–879.
[26]
Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, et al. (2010) Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9: 2068–2078.
[27]
Awasthi N, Schwarz MA, Schwarz RE (2011) Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 13: 597–604.
[28]
Schwarz MA, Kandel J, Brett J, Li J, Hayward J, et al. (1999) Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 190: 341–354.
[29]
Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, et al. (2000) Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 60: 70–80.
[30]
Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D, et al. (2010) Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther 9: 632–639.
[31]
Schwarz RE, Schwarz MA (2004) In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. J Surg Res 120: 64–72.
[32]
Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE (2009) Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest 89: 38–46.
[33]
Schwarz MA, Zheng H, Liu J, Corbett S, Schwarz RE (2005) Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp Cell Res 311: 229–239.
[34]
Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA (2010) EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. Ann Surg Oncol 17: 1442–1452.
[35]
Schwarz RE, Konduri S, Awasthi N, Cafasso D, Schwarz MA (2009) An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery 146: 241–249.
[36]
Awasthi N, Schwarz MA, Schwarz RE (2011) Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Cancer Chemother Pharmacol 68: 571–582.
[37]
Schwarz MA, Zhang F, Gebb S, Starnes V, Warburton D (2000) Endothelial monocyte activating polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis. Mech Dev 95: 123–132.
[38]
Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD (1999) An orthotopic in vivo model of human pancreatic cancer. Surgery 126: 562–567.
[39]
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.
[40]
Lee JJ, Kong M, Ayers GD, Lotan R (2007) Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 17: 461–480.
[41]
Konno H, Tanaka T, Matsuda I, Kanai T, Maruo Y, et al. (1995) Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int J Cancer 61: 268–271.
[42]
Satoh H, Ishikawa H, Fujimoto M, Fujiwara M, Yamashita YT, et al. (1998) Angiocytotoxic therapy in human non-small cell lung cancer cell lines–advantage of combined effects of TNP-470 and SN-38. Acta Oncol 37: 85–90.
[43]
Hayes AJ, Li LY, Lippman ME (2000) Anti-vascular therapy: a new approach to cancer treatment. West J Med 172: 39–42.
[44]
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392–401.
[45]
Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI (2007) Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. Exp Oncol 29: 267–271.
[46]
Crippa L, Gasparri A, Sacchi A, Ferrero E, Curnis F, et al. (2008) Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res 68: 1154–1161.
[47]
Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884–896.
[48]
Seandel M, Shia J, Linkov I, Maki RG, Antonescu CR, et al. (2006) The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clin Cancer Res 12: 6203–6204.
[49]
Bold RJ, Chandra J, McConkey DJ (1999) Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6: 279–285.
[50]
Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, et al. (2008) Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7: 638–647.
[51]
Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, et al. (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8: 35–45.
[52]
Zhang HP, Takayama K, Su B, Jiao XD, Li R, et al. (2011) Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res (Tokyo) 52: 1–8.
[53]
Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, et al. (2009) Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem 108: 1410–1417.
[54]
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62.
[55]
Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312: 1171–1175.
[56]
Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24–40.
